In this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.
In this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy.
Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.
Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.
At AACR 2018, Dr. Aung Naing of MD Anderson presented ECHO-203, the first data on epacadostat in combination with an anti–PD-L1 inhibitor.
Stage III colon cancer patients adhering to ACS Nutrition and Physical Activity Guidelines for Cancer Survivors after diagnosis had a 42% lower risk of death.
A biomarker known as RAD51 was found to be correlated with resistance to PARP inhibitor treatment in a study of breast cancer that harbors BRCA mutations.
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC.
At AACR 2018, Dr. Alexander Eggermont presented results of KEYNOTE-045/EORTC 1325-MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.
Implications of Mutation Profiling in Myeloid Malignancies—PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.
In this article, we review the published literature and evaluate secondary prevention strategies for nonmelanoma skin cancer. We also explore investigational therapies proposed for chemoprevention of nonmelanoma skin cancers.
In this article, we detail the experience with immune checkpoint inhibitors in patients with autoimmune disease.
Bilateral, Multifocal Renal Masses in a 35-Year-Old Man With a History of Tuberous Sclerosis Complex
A 35-year-old man with a known history of tuberous sclerosis complex was referred to the urology clinic by his primary care physician for consultation regarding bilateral, multifocal renal masses.